Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imipenem/cilastatin/relebactam versus piperacillin/tazobactam for hospital-acquired or ventilator-associated bacterial pneumonia
2018-003202-82Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Imipenem/cilastatin/relebactam with Piperacillin/tazobactam (2 arms). Primary endpoint: All-cause mortality. Started Feb 2019; status: completed.
02
Drugs
imipenem + cilastatin + relebactampiperacillin + tazobactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2018-003202-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003202-82.